Promoter hypermethylation-mediated silencing of the MLH1 gene was identified in 64% of CTCL patients showing microsatellite instability, suggesting that aberrant methylation of the MLH1 gene promoter may be important in disease progression in a subset of CTCL patients40. The gene discussed is MLH1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.